Calosyn Pharma Inc. is developing therapies for osteoarthritis (OA). OA is the leading cause of disability in the US, affecting 27 million people, and worldwide OA affects over 100 million people. Current therapies for OA leave a large portion of the OA patient population with nonideal options; we aim to help these patients.

Our product is based on a class of drugs known as calcium channel blockers. These drugs have been used safely in humans for many decades in the treatment of heart and vascular diseases. Taking advantage of new knowledge in how these drugs work and in how osteoarthritis results in joint damage and pain, we have reformulated and repurposed these drugs for injection directly into the osteoarthritic joint.

Calosyn Pharma is currently enrolling patients in a Phase II proof of efficacy clinical trial in the United States.